220904-17-6

Basic information

• Product Name: 2-BroMo-5-(1,3-dioxolan-2-yl)pyridine
• Synonyms: 2-BroMo-5-(1,3-dioxolan-2-yl)pyridine;2-BroMo-5-[1,3]dioxolan-2-yl-pyridine
• CAS NO: 220904-17-6
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230
• Mol File: 220904-17-6.mol

Chemical Properties

• Appearance: /
• Density: 1.593±0.06 g/cm3 (20 ºC 760 Torr)
• CAS DataBase Reference: 2-BroMo-5-(1,3-dioxolan-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-5-(1,3-dioxolan-2-yl)pyridine(220904-17-6)
• EPA Substance Registry System: 2-BroMo-5-(1,3-dioxolan-2-yl)pyridine(220904-17-6)

Safety Data

• Hazardous Substances Data: 220904-17-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Bromo-5-(1,3-dioxolan-2-yl)pyridine is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure allows for the formation of diverse chemical entities with potential applications in different industries.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-Bromo-5-(1,3-dioxolan-2-yl)pyridine is utilized as a reagent in the preparation of heterocyclic compounds. These heterocyclic compounds are essential in the development of new drugs with specific therapeutic properties.
Used in Anti-inflammatory Applications:
2-Bromo-5-(1,3-dioxolan-2-yl)pyridine has been investigated for its potential anti-inflammatory properties. Preliminary studies have shown promising results, indicating that it may be used as an anti-inflammatory agent in the future. Further research is needed to fully understand its mechanisms of action and potential applications in this area.
Used in Anti-tumor Applications:
Additionally, 2-Bromo-5-(1,3-dioxolan-2-yl)pyridine has been studied for its potential anti-tumor properties. Early research has demonstrated its effectiveness in inhibiting tumor growth, making it a promising candidate for further investigation and development as an anti-tumor agent. However, more extensive research is required to explore its full potential and understand its mechanisms of action in this context.

Upstream product

• 107-21-1 ethylene glycol 
• 149806-06-4 6-bromonicotinaldehyde 
• 624-28-2 2,5-dibromopyridine 
• 174608-37-8 2-bromo-5-(dimethoxymethyl)pyridine 

Downstream Products

• 671776-91-3 5-(1,3-dioxolan-2-yl)-2-cyano-pyridine 
• 1123838-17-4 x 
• 179873-48-4 2,2’-bipyridine-5-carbaldehyde 
• 131747-68-7 2-cyanopyridine-5-carboxyaldehyde 
• 1292309-87-5 C₂₁H₂₇NO₈S 
• 1342836-73-0 1-(4-(2-(5-(1,3-Dioxolan-2-yl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-2,3-difluorophenyl)-3-cyclopropylurea 
• 1342836-68-3 4-(2-(5-(1,3-Dioxolan-2-yl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-2,3-difluoroaniline 
• 1342828-76-5 1-Cyclopropyl-3-(2,3-difluoro-4-(2-(5-formylpyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea 

Relevant articles and documents

SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME

The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

Tandem vinyl radical Minisci-type annulation on pyridines: one-pot expeditious access to azaindenones

A new regiospecific alkylative/alkenylative cascade annulation of pyridines has been achieved whilst the corresponding classic Minisci alkylative annulation failed. This protocol provides a novel and expeditious access to azaindenones and related compoundsviacross-dehydrogenative coupling with the long-standing problem of C2/C4 regioselectivity of pyridines being well addressed.

Practical acetalization and transacetalization of carbonyl compounds catalyzed by recyclable PVP-I

A novel PVP-I catalyzed acetalizations/transacetalizations of carbonyl compounds has been developed processing with a mild and easy handling fashion. Different types of Acyclic and cyclic acetals were prepared from carbonyl compounds or their acetals successfully. Further applications of newly developed catalytic combination were testified. This protocol featured with simplicity of operation, mild reaction condition, short reaction time, recyclable of catalyst and broad substrates scope with excellent yields.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Spin-dimer networks: Engineering tools to adjust the magnetic interactions in biradicals

Magneto-structural correlations in stable organic biradicals have been studied on the example of weakly exchange coupled models with nitronyl nitroxide and imino nitroxide spin-carrying entities. Here, heteroatom substituted 2,2′-diaza- and 3,3′-diaza-tolane bridged biradicals were compared with the hydrocarbon analogue, while a biphenyl model with its 2,2′-bipyridine counterpart. For a 3,3′-diazatolane bridge the torsional angle between the nitronyl nitroxides and the pyridyl rings increased heavily (～52-54°) leading to a smaller theoretical intra-dimer exchange coupling value. However, a very large antiferromagnetic coupling was obtained experimentally. This could be appropriately explained by the presence of dominating inter-dimer exchange between the molecules. For the bis(imino nitroxide) with tolane bridge a field induced ordered state between 1.8 to 4.3 T in AC-susceptibility measurements was observed. In terms of a Bose Einstein condensate (BEC) of triplons this phenomenon could be described as a magnetic field induced ordered phase with 3D character.

Base Catalysis Enables Access to α,α-Difluoroalkylthioethers

A nucleophilic addition reaction of aryl thiols to readily available β,β-difluorostyrenes provides α,α-difluoroalkylthioethers. The reaction proceeds through an unstable anionic intermediate, prone to eliminate fluoride and generate α-fluorovinylthioethers. However, the use of base catalysis overcomes the facile β-fluoride elimination, generating α,α-difluoroalkylthioethers in excellent yields and selectivities.

NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel acrylamide derivatives of the formula (I) wherein R1, R 2, R 3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compo

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE

The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): (wherein R6 and R7 may be the same or different and each represent a hydrogen atom or the like, R8, R9, R19, and R11 may be the same or different and each represent a hydrogen atom or the like, R1 represents lower alkyl which may be substituted with cycloalkyl, or the like, and R3 represents optionally substituted aryl or an optionally substituted heterocyclic group).

Fluoride-18 radiolabeling of peptides bearing an aminooxy functional group to a prosthetic ligand via an oxime bond

We have developed a novel F-18 prosthetic ligand named fluoro-PEG- benzaldehyde (FPBA) 1. [18F]-FPBA 1 is formed in situ from its radiolabeled precursor [18F]6. Compound 6 is efficiently synthesized in four steps starting from commer

Inhibitors of Protein Tyrosine Kinase Activity

This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.